MX2023006397A - Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. - Google Patents
Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.Info
- Publication number
- MX2023006397A MX2023006397A MX2023006397A MX2023006397A MX2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A MX 2023006397 A MX2023006397 A MX 2023006397A
- Authority
- MX
- Mexico
- Prior art keywords
- trem2
- dysfunction
- atp
- agonists
- treatment
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 title 1
- 101710205202 Phospholipid-transporting ATPase ABCA1 Proteins 0.000 title 1
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 7
- 101710174937 Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 abstract 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para tratar una enfermedad o trastorno causado por y/o asociado con una disfunción del ABCD1 en un paciente humano, el método comprende administrar al paciente que lo necesita una cantidad eficaz de un compuesto que aumenta la actividad del receptor activador expresado en células mieloides 2 (TREM2). En algunas modalidades, el compuesto que aumenta la actividad de TREM2 es un agonista de TREM2. En algunas modalidades, el agonista de TREM2 es un agonista de molécula pequeña de TREM2 o un agonista de anticuerpo de TREM2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121404P | 2020-12-04 | 2020-12-04 | |
| PCT/US2021/072749 WO2022120390A1 (en) | 2020-12-04 | 2021-12-06 | Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006397A true MX2023006397A (es) | 2023-08-11 |
Family
ID=81854825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006397A MX2023006397A (es) | 2020-12-04 | 2021-12-06 | Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230082623A1 (es) |
| EP (1) | EP4255567A1 (es) |
| JP (1) | JP2023552553A (es) |
| KR (1) | KR20230130630A (es) |
| CN (1) | CN117015400A (es) |
| AU (1) | AU2021392813A1 (es) |
| CA (1) | CA3203783A1 (es) |
| IL (1) | IL303261A (es) |
| MX (1) | MX2023006397A (es) |
| TW (1) | TW202237186A (es) |
| WO (1) | WO2022120390A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024052343A1 (en) * | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Trem-2 agonists for the treatment of marfan syndrome |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117069841A (zh) * | 2015-10-06 | 2023-11-17 | 艾利妥 | 抗trem2抗体及其使用方法 |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| US20200309788A1 (en) * | 2017-09-29 | 2020-10-01 | The General Hospital Corporation | Methods for identifying and treating adrenomyeloneuropathy (amn) |
| EP3732193A1 (en) * | 2017-12-29 | 2020-11-04 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
| TW202208355A (zh) * | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
-
2021
- 2021-12-06 MX MX2023006397A patent/MX2023006397A/es unknown
- 2021-12-06 CA CA3203783A patent/CA3203783A1/en active Pending
- 2021-12-06 WO PCT/US2021/072749 patent/WO2022120390A1/en active Application Filing
- 2021-12-06 AU AU2021392813A patent/AU2021392813A1/en active Pending
- 2021-12-06 EP EP21901669.8A patent/EP4255567A1/en active Pending
- 2021-12-06 IL IL303261A patent/IL303261A/en unknown
- 2021-12-06 TW TW110145447A patent/TW202237186A/zh unknown
- 2021-12-06 JP JP2023534102A patent/JP2023552553A/ja active Pending
- 2021-12-06 CN CN202180092981.5A patent/CN117015400A/zh active Pending
- 2021-12-06 KR KR1020237022491A patent/KR20230130630A/ko unknown
- 2021-12-06 US US17/457,727 patent/US20230082623A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202237186A (zh) | 2022-10-01 |
| US20230082623A1 (en) | 2023-03-16 |
| WO2022120390A1 (en) | 2022-06-09 |
| AU2021392813A1 (en) | 2023-06-29 |
| KR20230130630A (ko) | 2023-09-12 |
| CN117015400A (zh) | 2023-11-07 |
| CA3203783A1 (en) | 2022-06-09 |
| EP4255567A1 (en) | 2023-10-11 |
| JP2023552553A (ja) | 2023-12-18 |
| IL303261A (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20230069A (es) | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 | |
| Taheri et al. | The role of hypocretins (orexins) in sleep regulation and narcolepsy | |
| Stankov et al. | The melatonin receptor: distribution, biochemistry, and pharmacology | |
| Kluger | Fever revisited | |
| KR101754045B1 (ko) | 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법 | |
| RU2010108429A (ru) | Регуляторы ммр-9 и их применение | |
| Przeklasa-Muszyńska et al. | Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients | |
| JPS59130215A (ja) | 錐体外運動障害の軽減法 | |
| MX2023006397A (es) | Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. | |
| Riehl et al. | Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy | |
| McLennan | The effect of some catecholamines upon a monosynaptic reflex pathway in the spinal cord | |
| Mrazova et al. | Influence of medetomidine, acepromazine, fentanyl and butorphanol on intraocular pressure and pupil size in healthy dogs. | |
| Kim et al. | Biochemical and functional characterization of alpha-adrenergic receptors in the rabbit vagina | |
| Zaytseva et al. | Ketamine’s rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors | |
| EP3468602B1 (en) | Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain | |
| Sun et al. | A sub-threshold dose of pilocarpine increases glutamine synthetase in reactive astrocytes and enhances the progression of amygdaloid-kindling epilepsy in rats | |
| Donoso | Localized increase of GABA levels in brain areas of the rat and inhibition of the plasma LH rise following orchidectomy | |
| Ramkissoon et al. | G protein-coupled receptors in haematopoietic disruption | |
| Macchitelli et al. | Changes in behavior and electrocortical activity in the monkey following administration of 5-hydroxytryptophan (5-HTP) | |
| Hu et al. | Low-dose interleukin-2 and regulatory T cell treatments attenuate punctate and dynamic mechanical allodynia in a mouse model of sciatic nerve injury | |
| Ragule et al. | Update on the physiologic effects of ketamine in general anesthesia and spinal blockade: a review of the literature | |
| Scurr et al. | Trials of perphenazine in the prevention of post-operative vomiting | |
| KR20180015085A (ko) | 신경퇴행성 질환의 예방 또는 치료를 위한 약제학적 조성물 | |
| Martignoni et al. | Abnormal dexamethasone suppression test in daily chronic headache sufferers | |
| Potter et al. | Modulation of sympathetic neurotransmission by neuropeptide YY 2 receptors in rats and guinea pigs |